Evogene Ltd. has entered into a research collaboration with the Queensland University of Technology (QUT) to accelerate the discovery and optimization of small‑molecule therapies for chemotherapy‑ and targeted‑therapy‑resistant non‑small cell lung cancer (NSCLC). The partnership will combine Evogene’s ChemPass AI generative‑design platform with QUT’s cancer‑genomics expertise, focusing on a newly identified detoxification pathway that drives cisplatin resistance in NSCLC. This marks the first time ChemPass AI is being applied in oncology, positioning Evogene to validate its multiparameter optimization capability in a high‑value therapeutic area.
The collaboration signals a decisive shift in Evogene’s business model. Historically an agricultural AI company, Evogene has been divesting non‑core assets and concentrating on its ChemPass AI engine for drug discovery. By partnering with a leading research institution, Evogene aims to attract early‑stage pharmaceutical partners and demonstrate that its AI platform can generate clinically relevant leads in a disease area with a 60‑70% intrinsic resistance rate to cisplatin and a 30‑40% failure rate for upfront targeted therapies.
Evogene’s recent financial performance provides context for the partnership. In Q3 2025 the company posted a net income of $5.2 million, a turnaround from a $8.2 million loss in Q3 2024, driven largely by income from asset sales and a sharp reduction in operating expenses from $5.9 million to $2.9 million. Revenue for the quarter was $310,000, missing analyst estimates of $650,000, and the company’s cash position stood at $16.0 million as of September 30, 2025. The partnership is therefore part of a broader strategy to rebuild profitability and diversify revenue streams.
CEO Ofer Haviv has described Evogene as “at a turning point—becoming a focused, AI‑driven company built around our core engine, ChemPass AI.” He emphasized that the QUT collaboration is a key milestone in proving the platform’s value to the pharmaceutical sector and in establishing Evogene as a credible partner for early‑stage drug discovery.
Analyst coverage of Evogene remains mixed. A “Strong Buy” consensus rating was issued by one analyst, while other reports noted a “Moderate Buy” from three analysts and a “Strong Sell” from 26 analysts over the preceding three months. The partnership is expected to influence future analyst sentiment by demonstrating the platform’s applicability beyond agriculture, but the company’s current revenue miss and cash constraints temper enthusiasm.
The collaboration offers both opportunities and headwinds. On the upside, validating ChemPass AI in oncology could unlock new revenue streams and attract pharma partnerships, reinforcing Evogene’s strategic pivot. On the downside, the company’s recent revenue miss and cash position highlight ongoing financial challenges, underscoring the need for disciplined cost management while investing in high‑risk, high‑reward research. Overall, the partnership represents a significant step toward establishing Evogene as a player in drug discovery, but its long‑term impact will depend on the success of the research and the company’s ability to translate AI‑generated leads into commercial products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.